Manhattan Scientifics (MHTX: OTCQB) announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. More information can be found in the company’s recent 8-K filing.

A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer's disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.

Featuring a revolutionary combination of speed and accuracy, Elekta’s new Versa HD™ system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10.

Scientists at the ATR Computation Neuroscience Laboratories in Kyoto, Japan, have found a way to predict what a person is dreaming about based on fMRI scans of dreamers.

Older women with an extended period of time between their last mammogram and breast cancer diagnosis were at an increased risk for breast cancer mortality, suggesting a role for continued mammography screening among women aged 75 years and older, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

As radiation exposure continues to grab headlines and patients ply physicians with questions, more providers are transitioning to low-dose imaging. However, the road to low-dose CT is riddled with potholes.

Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute are conducting the nation’s first randomized controlled dementia screening trial to weigh the benefits and risks of routine screening for dementia. The results of the five-year trial will help policy-makers, individuals and families weigh the pros and cons of routine screening of adults age 65 and older.